MX2012004295A - Composicion para el tratamiento de esclerosis multiple. - Google Patents

Composicion para el tratamiento de esclerosis multiple.

Info

Publication number
MX2012004295A
MX2012004295A MX2012004295A MX2012004295A MX2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A MX 2012004295 A MX2012004295 A MX 2012004295A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
mbp
oligopeptides
progression
binding
Prior art date
Application number
MX2012004295A
Other languages
English (en)
Inventor
Jr A A Belogurov
Ponomarenko
A G Gabibov
Original Assignee
Lifebio Lab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifebio Lab Llc filed Critical Lifebio Lab Llc
Publication of MX2012004295A publication Critical patent/MX2012004295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los nuevos oligopéptidos, combinaciones de estos y proteínas de fusión compuestos por los oligopéptidos antes descritos son revelados. Los oligopéptidos son homólogos en las secuencias de aminoácidos a las partes seleccionadas de la secuencia de aminoácidos en la proteína básica de mielina (MBP) humana y son capaces de aliviar la progresión de la esclerosis múltiple por medio de la unió e inactividad de los anti auto anticuerpos de epitopo especifico de MBP (ESAMPCAA) involucrados en la unión y degradación catalítica de la MBP en el curso de la progresión de la Esclerosis Múltiple.
MX2012004295A 2009-10-12 2009-10-12 Composicion para el tratamiento de esclerosis multiple. MX2012004295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2009/000533 WO2011046462A1 (en) 2009-10-12 2009-10-12 Composition for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2012004295A true MX2012004295A (es) 2012-08-15

Family

ID=42651912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004295A MX2012004295A (es) 2009-10-12 2009-10-12 Composicion para el tratamiento de esclerosis multiple.

Country Status (12)

Country Link
US (1) US9896491B2 (es)
EP (1) EP2488196B1 (es)
JP (1) JP5709876B2 (es)
KR (1) KR20120103591A (es)
CN (1) CN102781465A (es)
AU (1) AU2009354040A1 (es)
CA (1) CA2780961C (es)
DK (1) DK2488196T3 (es)
EA (1) EA024832B1 (es)
ES (1) ES2566230T3 (es)
MX (1) MX2012004295A (es)
WO (1) WO2011046462A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
AU2013246870B2 (en) * 2012-04-11 2016-06-23 Lipoxen Technologies Limited Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
WO2014152831A2 (en) * 2013-03-14 2014-09-25 Health Research, Inc. Targeting peptides and uses thereof
WO2015023132A1 (ko) * 2013-08-14 2015-02-19 주식회사 카엘젬백스 다발성 경화증 치료 및 예방용 조성물
CN105541992A (zh) * 2015-11-04 2016-05-04 武汉云克隆诊断试剂研究所有限公司 人MBP18.5kD变体抗原表位肽及特异性检测试剂盒
CN110317254A (zh) * 2018-03-28 2019-10-11 深圳市安群生物工程有限公司 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
IL115766A0 (en) 1994-10-25 1996-01-19 Immulogic Pharma Corp Composition and treatment for multiple sclerosis
CA2494338C (en) 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CN102764425B (zh) 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
WO2008151847A1 (en) * 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Autoantibody binding peptides and their use for the treatment of vascular diseases
EP2197906A1 (en) * 2007-10-11 2010-06-23 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Fusion polypeptide comprising s-antigen repeat units
WO2009056833A2 (en) * 2007-10-31 2009-05-07 Apitope Technology (Bristol) Limited Composition

Also Published As

Publication number Publication date
JP5709876B2 (ja) 2015-04-30
JP2013507437A (ja) 2013-03-04
US9896491B2 (en) 2018-02-20
CN102781465A (zh) 2012-11-14
EP2488196B1 (en) 2015-12-16
CA2780961A1 (en) 2011-04-21
KR20120103591A (ko) 2012-09-19
ES2566230T3 (es) 2016-04-11
EA201290185A1 (ru) 2012-11-30
CA2780961C (en) 2018-10-02
WO2011046462A1 (en) 2011-04-21
EP2488196A1 (en) 2012-08-22
AU2009354040A1 (en) 2012-05-31
EA024832B1 (ru) 2016-10-31
US20120207820A1 (en) 2012-08-16
DK2488196T3 (en) 2016-03-14

Similar Documents

Publication Publication Date Title
MX2012004295A (es) Composicion para el tratamiento de esclerosis multiple.
IN2014CN00414A (es)
MY156286A (en) Human il-23 antigen binding proteins
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
EA201270775A1 (ru) Связывающие сывороточный альбумин молекулы
WO2012088461A3 (en) Linker peptides and polypeptides comprising same
IL223989B (en) Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto
RU2016146198A (ru) Терапевтические dll4-связывающие белки
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
MX348071B (es) Variantes de fc.
UA104663C2 (en) Antibody binding to cd127
WO2009142460A3 (en) Antibody-peptide fused synergibody
MY160552A (en) Low protein infant formula with increased essential amino acids
IL225538A0 (en) Methods for the identification of anti-immune reaction peptides of anti-citrullinates
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
EP2805973A3 (en) Humanised antibodies to Toll-like receptor 2 and uses thereof
WO2012083078A3 (en) Croos-linked peptides and proteins, methods of making same, and uses thereof
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2010136483A3 (en) Antigen-binding proteins
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal